Methods for the treatment and prevention of inflammatory diseases

• US 20060270630A1
• Filed: 05/19/2006
• Published: 11/30/2006
• Est. Priority Date: 05/20/2005
• Status: Active Grant

• Current Assignee: Apogen Technologies Incorporated (Perspecta, Inc.)
• Original Assignee: Apogen Technologies Incorporated (Perspecta, Inc.)
• Inventors: Smith, Charles D., French, Kevin J., Maines, Lynn W.
• Granted Patent: US 8,324,237 B2
• Time in Patent Office: Days
• US Class Current: 514/78
• CPC Class Codes: A61K 31/685 one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin

Abstract

The invention includes processes mainly for the treatment of a inflammatory diseases, such as inflammatory bowel disease, arthritis, atherosclerosis, asthma, allergy, inflammatory kidney disease, circulatory shock, multiple sclerosis, chronic obstructive pulmonary disease, skin inflammation, periodontal disease, psoriasis and T cell-mediated diseases of immunity, including allergic encephalomyelitis, allergic neuritis, transplant allograft rejection, graft versus host disease, myocarditis, thyroiditis, nephritis, systemic lupus erthematosus, and insulin-dependent diabetes mellitus. The processes involve treating a patient with a pharmaceutical composition containing an active ingredient that inhibits the activity of sphingosine kinase.

Claims

1. A method for treating an inflammatory disease comprising delivering to a patient a compound or pharmaceutical composition in an amount effective to inhibit sphingosine kinase activity.

2. A method of claim 1 wherein said inflammatory disease is selected from the group consisting of inflammatory bowel disease, arthritis, atherosclerosis, asthma, allergy, inflammatory kidney disease, circulatory shock, multiple sclerosis, chronic obstructive pulmonary disease, skin inflammation, periodontal disease, psoriasis and T cell-mediated diseases of immunity.

3. A method of claim 2 wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis, Crohn'"'"'s Disease and indeterminate colitis.

4. A method of claim 2 wherein said T cell-mediated diseases of immunity is selected from the group consisting of allergic encephalomyelitis, allergic neuritis, transplant allograft rejection, graft versus host disease, myocarditis, thyroiditis, nephritis, systemic lupus erthematosus, and insulin-dependent diabetes mellitus.

5. A method of claim 2 wherein said arthritis is selected from the group consisting of rheumatoid arthritis, osteoarthritis, Caplan'"'"'s Syndrome, Felty'"'"'s Syndrome, Sjogren'"'"'s Syndrome, ankylosing spondylitis, Still'"'"'s Disease, Chondrocalcinosis, gout, rheumatic fever, Reiter'"'"'s Disease and Wissler'"'"'s Syndrome.

6. A method of claim 2 wherein said inflammatory kidney disease is selected from the group consisting of glomerulonephritis, glomerular injury, nephrotic syndrome, interstitial nephritis, lupus nephritis, Goodpasture'"'"'s disease, Wegener'"'"'s granulomatosis, renal vasculitis, IgA nephropathy and idiopathic glomerular disease.

7. A method of claim 2 wherein said skin inflammation is selected from the group consisting of psoriasis, atopic dermatitis, contact sensitivity and acne.